Topical microbicides and HIV prevention in the female genital tract

Journal of Clinical Pharmacology

Volumn 54, Issue 6, 2014, Pages 603-615

  Cottrell, MacKenzie L ^a   Kashuba, Angela D M ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

female genital tract; HIV prevention; microbicide; pre exposure prophylaxis; tenofovir gel

Indexed keywords

ACICLOVIR; CONTRACEPTIVE AGENT; DAPIVIRINE; EMTRICITABINE; ETHINYLESTRADIOL PLUS ETONOGESTREL; MARAVIROC; MICROBICIDE; NEVIRAPINE; PLACEBO; POLYANION; PRO 2000; SURFACTANT; TENOFOVIR; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TOPICAL ANTIINFECTIVE AGENT;

ANTIVIRAL ACTIVITY; ARTICLE; CHEMOPROPHYLAXIS; DRUG MECHANISM; FEMALE GENITAL SYSTEM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); TOPICAL TREATMENT; VAGINA RING; ANIMAL; FEMALE; HIV INFECTIONS; MEDICATION COMPLIANCE;

ANIMALS; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS, LOCAL; FEMALE; GENITALIA, FEMALE; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE;

EID: 84899816995     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.292     Document Type: Article

References (109)

1. Centers for Disease Control and Prevention. HIV prevention. http://www.cdc.gov/hiv/basics/prevention.html. Updated 2014. Accessed January14, 2014.
2. Langen TT,. Gender power imbalance on women's capacity to negotiate self-protection against HIV/AIDS in Botswana and South Africa. Afr Health Sci. 2005; 5 (3): 188-197.
3. World Health Organization (WHO). Gender women and health: Gender inequalities and HIV. http://www.who.int/gender/hiv-aids/en/. Updated 2014. Accessed January 4, 2014.
4. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 (5): 399-410.
5. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367 (5): 423-434.
6. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367 (5): 411-422.
7. Marrazzo J, Ramjee G, Nair G,. et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir/emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections. 2013;Atlanta, GA, March 36:Abstract 26LB.
8. Truvada full prescribing information. Foster City, CA 94404: Gilead Sciences, Inc; 2012.
9. Romano JW, Robbiani M, Doncel GF, Moench T,. Non-specific microbicide product development: then and now. Curr HIV Res. 2012; 10 (1): 9-18.
10. Miller CJ, Alexander NJ, Gettie A, Hendrickx AG, Marx PA,. The effect of contraceptives containing nonoxynol-9 on the genital transmission of simian immunodeficiency virus in rhesus macaques. Fertil Steril. 1992; 57 (5): 1126-1128.
11. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA. 1992; 268 (4): 477-482.
12. Zekeng L, Feldblum PJ, Oliver RM, Kaptue L,. Barrier contraceptive use and HIV infection among high-risk women in Cameroon. AIDS. 1993; 7 (5): 725-731.
13. Roddy RE, Cordero M, Cordero C, Fortney JA,. A dosing study of nonoxynol-9 and genital irritation. Int J STD AIDS. 1993; 4 (3): 165-170.
14. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL,. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998; 339 (8): 504-510.
15. Van Damme L, Niruthisard S, Atisook R, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS. 1998; 12 (4): 433-437.
16. Van Damme L, Chandeying V, Ramjee G, et al. Safety of multiple daily applications of COL-1492, a nonoxynol-9 vaginal gel, among female sex workers. COL-1492 phase II study group. AIDS. 2000; 14 (1): 85-88.
17. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet. 2002; 360 (9338): 971-977.
18. Chvapil M, Droegemueller W, Owen JA, Eskelson CD, Betts K,. Studies of nonoxynol-9. I. The effect on the vaginas of rabbits and rats. Fertil Steril. 1980; 33 (4): 445-450.
19. Niruthisard S, Roddy RE, Chutivongse S,. The effects of frequent nonoxynol-9 use on the vaginal and cervical mucosa. Sex Transm Dis. 1991; 18 (3): 176-179.
20. Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R,. A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength gynol II. Contraception. 2004; 70 (3): 233-240.
21. Mauck CK, Frezieres RG, Walsh TL, Schmitz SW, Callahan MM, Bax R,. Male tolerance study of 1% C31G. Contraception. 2004; 70 (3): 221-225.
22. Mauck CK, Creinin MD, Barnhart KT, et al. A phase I comparative postcoital testing study of three concentrations of C31G. Contraception. 2004; 70 (3): 227-231.
23. Ballagh SA, Baker JM, Henry DM, Archer DF,. Safety of single daily use for one week of C31G HEC gel in women. Contraception. 2002; 66 (5): 369-375.
24. Peterson L, Nanda K, Opoku BK, et al. SAVVY (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS ONE. 2007; 2 (12): e1312.
25. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS ONE. 2008; 3 (1): e1474.
26. Pirrone V, Wigdahl B, Krebs FC,. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res. 2011; 90 (3): 168-182.
27. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008; 372 (9654): 1977-1987.
28. Kilmarx PH, Paxton L,. Need for a true placebo for vaginal microbicide efficacy trials. Lancet. 2003; 361 (9359): 785-786. author reply 786.
29. Tien D, Schnaare RL, Kang F, et al. In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS Res Hum Retroviruses. 2005; 21 (10): 845-853.
30. Doh AS, Ngoh N, Roddy R, Lai JJ, Linton K, Mauck C,. Safety and acceptability of 6% cellulose sulfate vaginal gel applied four times per day for 14 days. Contraception. 2007; 76 (3): 245-249.
31. Mauck C, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a phase I safety and colposcopy study. Contraception. 2001; 64 (6): 383-391.
32. Malonza IM, Mirembe F, Nakabiito C, et al. Expanded phase I safety and acceptability study of 6% cellulose sulfate vaginal gel. AIDS. 2005; 19 (18): 2157-2163.
33. El-Sadr WM, Mayer KH, Maslankowski L, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006; 20 (8): 1109-1116.
34. Schwartz JL, Mauck C, Lai JJ, et al. Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind phase I safety study. Contraception. 2006; 74 (2): 133-140.
35. Mauck C, Frezieres R, Walsh T, Robergeau K, Callahan M,. Cellulose sulfate: tolerance and acceptability of penile application. Contraception. 2001; 64 (6): 377-381.
36. Jespers V, Buve A, Van Damme L,. Safety trial of the vaginal microbicide cellulose sulfate gel in HIV-positive men. Sex Transm Dis. 2007; 34 (7): 519-522.
37. Halpern V, Ogunsola F, Obunge O, et al. Effectiveness of cellulose sulfate vaginal gel for the prevention of HIV infection: results of a phase III trial in Nigeria. PLoS ONE. 2008; 3 (11): e3784.
38. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med. 2008; 359 (5): 463-472.
39. Mesquita PM, Cheshenko N, Wilson SS, et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis. 2009; 200 (4): 599-608.
40. Abdool Karim SS, Richardson BA, Ramjee G, et al. Safety and effectiveness of BufferGel and 0. 5% PRO2000 gel for the prevention of HIV infection in women. AIDS. 2011; 25 (7): 957-966.
41. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (microbicides development programme 301): a phase 3, randomised, double-blind, parallel-group trial. Lancet. 2010; 376 (9749): 1329-1337.
42. Shattock RJ, Doms RW,. AIDS models: microbicides could learn from vaccines. Nat Med. 2002; 8 (5): 425.
43. Grant RM, Hamer D, Hope T, et al. Whither or wither microbicides?. Science. 2008; 321 (5888): 532-534.
44. Van Rompay KK,. The use of nonhuman primate models of HIV infection for the evaluation of antiviral strategies. AIDS Res Hum Retroviruses. 2012; 28 (1): 16-35.
45. Denton PW, Garcia JV,. Mucosal HIV-1 transmission and prevention strategies in BLT humanized mice. Trends Microbiol. 2012; 20 (6): 268-274.
46. Romano J, Kashuba A, Becker S, et al. Pharmacokinetics and pharmacodynamics in HIV prevention; current status and future directions: a summary of the DAIDS and BMGF sponsored think tank on pharmacokinetics (PK)/pharmacodynamics (PD) in HIV prevention. AIDS Res Hum Retroviruses. 2013; 29 (11): 1418-1427.
47. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010; 329 (5996): 1168-1174.
48. Micorbicide Trial Network (MTN). MTN statement on decision to discontinue use of tenofovir gel in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3909 Web site. PublishedNovember 25, 2011. Updated 2011. Accessed December 10, 2013.
49. CONRAD. Tenofovir gel overview. http://www.conrad.org/tenofovir.html. Updated 2013. Accessed December 11, 2013.
50. Shattock RJ, Rosenberg Z,. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med. 2012; 2 (2): a007385.
51. Wainberg M,. The prospect for RT inhibitors as topical microbicides. Microbicides 2004 Conference. 2004;London, England:Abstract MMM-03.
52. Gengiah TN, Baxter C, Mansoor LE, Kharsany AB, Abdool Karim SS,. A drug evaluation of 1% tenofovir gel and tenofovir disoproxil fumarate tablets forthe prevention of HIV infection. Expert Opin Investig Drugs. 2012; 21 (5): 695-715.
53. Dobard C, Sharma S, Martin A, et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol. 2012; 86 (2): 718-725.
54. Anton PA, Cranston RD, Kashuba A, et al. RMP-02/MTN-006: a phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses. 2012; 28 (11): 1412-1421.
55. Nicol M, Emerson C, Nelson J,. et al. Tenofovir diphosphate concentration-response relationship for HIV prevention in vaginal tissue. 21st Conference on Retroviruses and Opportunistic Infections. 2014;Boston, MA: Abstract 512.
56. Mayer KH, Maslankowski LA, Gai F, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006; 20 (4): 543-551.
57. Schwartz JL, Poindexter A, Wheeless A, Mauck CK, Callahan MM,. Safety evaluation of 1% tenofovir gel in healthy men. Int J STD AIDS. 2009; 20 (6): 384-386.
58. Dezzutti CS, Rohan LC, Wang L, et al. Reformulated tenofovir gel for use as a dual compartment microbicide. J Antimicrob Chemother. 2012; 67 (9): 2139-2142.
59. McGowan I, Hoesley C, Cranston RD, et al. A phase 1 randomized, double blind, placebo controlled rectal safety and acceptability study of tenofovir 1% gel (MTN-007). PLoS ONE. 2013; 8 (4): e60147.
60. McGowan I,. The development of rectal microbicides for HIV prevention. Expert Opin Drug Deliv. 2014; 11 (1): 69-82.
61. Baggaley RF, Dimitrov D, Owen BN, et al. Heterosexual anal intercourse: a neglected risk factor for HIV? Am J Reprod Immunol. 2013; 69 (Suppl 1): 95-105.
62. Minani I, Alary M, Lowndes C,. et al. Higher levels of HIV-related risky behavior in polling booth surveys compared to face-to-face interviews in a general population survey in Cotonou. 18th International Society of Sexually Transmitted Disease Research. 2009;London, England:Abstract OS1.8.03.
63. Gorbach PM, Mensch BS, Husnik M, et al. Effect of computer-assisted interviewing on self-reported sexual behavior data in a microbicide clinical trial. AIDS Behav. 2013; 17 (2): 790-800.
64. Hanck SE, Blankenship KM, Irwin KS, West BS, Kershaw T,. Assessment of self-reported sexual behavior and condom use among female sex workers in India using a polling box approach: a preliminary report. Sex Transm Dis. 2008; 35 (5): 489-494.
65. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003; 362 (9387): 859-868.
66. Karim SS, Kashuba AD, Werner L, Karim QA,. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet. 2011; 378 (9787): 279-281.
67. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363 (27): 2587-2599.
68. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok tenofovir study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013; 381 (9883): 2083-2090.
69. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367 (5): 399-410.
70. Karim SS, Karim QA,.Effectiveness and safety of vaginal microbicide 1% tenofovir gel for prevention of HIV infection in women. XVIII International AIDS Conference. 2010;Vienna, Austria:Abstract TUSS0204 and oral presentation.
71. Mensch BS, van der Straten A, Katzen LL,. Acceptability in microbicide and PrEP trials: current status and a reconceptualization. Curr Opin HIV AIDS. 2012; 7 (6): 534-541.
72. Frezieres RG, Walsh T, Kilbourne-Brook M, Coffey PS,. Couples' acceptability of the SILCS diaphragm for microbicide delivery. Contraception. 2012; 85 (1): 99-107.
73. van der Straten A, Montgomery ET, Cheng H, et al. High acceptability of a vaginal ring intended as a microbicide delivery method for HIV prevention in African women. AIDS Behav. 2012; 16 (7): 1775-1786.
74. Giguere R, Carballo-Dieguez A, Ventuneac A, et al. Variations in microbicide gel acceptability among young women in the USA and Puerto Rico. Cult Health Sex. 2012; 14 (2): 151-166.
75. Carballo-Dieguez A, Giguere R, Dolezal C, et al. "Tell juliana": acceptability of the candidate microbicide VivaGel(R) and two placebo gels among ethnically diverse, sexually active young women participating in a phase 1 microbicide study. AIDS Behav. 2012; 16 (7): 1761-1774.
76. Gengiah TN, Moosa A, Naidoo A, Mansoor LE,. Adherence challenges with drugs for pre-exposure prophylaxis to prevent HIV infection. Int J Clin Pharm. 2014; 36 (1): 70-85.
77. Minnis AM, Gandham S, Richardson BA, et al. Adherence and acceptability in MTN 001: a randomized cross-over trial of daily oral and topical tenofovir for HIV prevention in women. AIDS Behav. 2013; 17 (2): 737-747.
78. Galea JT, Kinsler JJ, Salazar X, et al. Acceptability of pre-exposure prophylaxis as an HIV prevention strategy: barriers and facilitators to pre-exposure prophylaxis uptake among at-risk Peruvian populations. Int J STD AIDS. 2011; 22 (5): 256-262.
79. van der Straten A, Stadler J, Montgomery E, et al. Women's experiences with oral and vaginal pre-exposure prophylaxis: the VOICE-C qualitative study in Johannesburg, South Africa. PLoS ONE. 2014; 9 (2): e89118.
80. Hillier S,. HIV prevention research: Progress and challenges. 21st Conference on Retroviruses and Opportunistic Infections. 2014; Boston, MA:Oral presentation.
81. Hendrix CW, Chen BA, Guddera V, et al. MTN-001: randomized pharmacokinetic cross-over study comparing tenofovir vaginal gel and oral tablets in vaginal tissue and other compartments. PLoS ONE. 2013; 8 (1): e55013.
82. European Medicines Agency. Scientific discussion for the approval of viread. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Scientific- Discussion/human/000419/WC500051732.pdf. Updated 2004. Accessed Febuary 20, 2014.
83. Food US, Drug Administration,. Viread (tenofovir disoproxil fumarate) label update. http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/ HIVandAIDSActivities/ucm125021.htm. Updated 2009. Accessed Febuary 20, 2014.
84. Ayers KM, Clive D, Tucker WE, Jr, Hajian G, de Miranda P,. Nonclinical toxicology studies with zidovudine: genetic toxicity tests and carcinogenicity bioassays in mice and rats. Fundam Appl Toxicol. 1996; 32 (2): 148-158.
85. Smith J, Rastogi R, Teller R,. et al. A tenofovir disoproxil fumarate intravaginal ring completely protects against repeated SHIV vaginal challenge in nonhuman primates. 20th Conference on Retroviruses and Opportunistic Infections. 2013;Atlanta, Georgia.
86. Smith J, Rastogi R, Teller R,. et al. A novel intravaginal ring design releasing tenofovir delivers comparable tenofovir diphosphate levels in vaginal target cells in macaques to gel dosing. 20th Conference on Retroviruses and Opportunistic Infections. 2013;Atlanta, GA.
87. ClinicalTrials. gov. Safety and pharmacokinetics (PK) of a polyurethane tenofovir disoproxil fumarate (TDF) vaginal ring (TDF IVR-001). http://clinicaltrials.gov/ct2/show/NCT02006264?term=tenofovir+ring&rank=1. Published 2013. Updated 2013. Accessed December 11, 2013.
88. Schader SM, Oliveira M, Ibanescu RI, Moisi D, Colby-Germinario SP, Wainberg MA,. In vitro resistance profile of the candidate HIV-1 microbicide drug dapivirine. Antimicrob Agents Chemother. 2012; 56 (2): 751-756.
89. Woolfson AD, Umrethia ML, Kett VL, Malcolm Freeze-dried RK,. Mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimisation by an artificial neural network. Int J Pharm. 2010; 388 (1-2): 136-143.
90. Akil A, Parniak MA, Dezzuitti CS, et al. Development and characterization of a vaginal film containing dapivirine, a non- nucleoside reverse transcriptase inhibitor (NNRTI), for prevention of HIV-1 sexual transmission. Drug Deliv Transl Res. 2011; 1 (3): 209-222.
91. Malcolm RK, Woolfson AD, Toner CF, Morrow RJ, McCullagh Long-term SD,. Controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother. 2005; 56 (5): 954-956.
92. Nel A, Smythe S, Young K, et al. Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women. J Acquir Immune Defic Syndr. 2009; 51 (4): 416-423.
93. Romano J, Variano B, Coplan P, et al. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. AIDS Res Hum Retroviruses. 2009; 25 (5): 483-488.
94. Nel A, Kamupira M, Woodsong C,. et al. Safety, acceptability and pharmacokinetic assessment (adherence) of monthly dapivirine vaginal microbicide rings (ring-004) for HIV prevention. 19th Conference on Retrovirus and Opportunistic Infections. 2012;Seattle, WA.
95. van't Klooster G, van der Geest R, Gille D,. Pharmacokinetics, tolerability and safety of multiple oral doses of TMC120 (R147681) in 32 healthy subjects. Tibotec Pharmaceuticals Ltd Trial No TIBO-0001104. April 9, 2004;TMC120- C104-CRR.
96. ClinicalTrials. gov. Safety and efficacy trial of a dapivirine vaginal matrix ring in healthy HIV-negative women. http://clinicaltrials.gov/ct2/show/ NCT01539226?term=The+Ring+Study+AND+dapivirine&rank=12. Updated 2013. Accessed January 5, 2014.
97. ClinicalTrials. gov. Phase 3 safety and effectiveness trial of dapivirine vaginal ring for prevention of HIV-1 in women (ASPIRE). http://clinicaltrials. gov/ct2/show/NCT01617096?term=01617096&rank=1. Updated 2012. Accessed January 10, 2014.
98. ClinicalTrials. gov. Safety and pharmacokinetics of dapirivine/maraviroc vaginal ring. http://clinicaltrials.gov/ct2/show/NCT01363037?term= NCT01363037&rank=1. Updated 2013. Accessed December 11, 2013.
99. Moss JA, Malone AM, Smith TJ, et al. Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother. 2012; 56 (2): 875-882.
100. van der Straten A, Brown E, Marrazzo J,. et al. Divergent adherence estimates with pharmacokinetic and behavioral measures in VOICE (MTN003). 21st Conference on Retroviruses and Opportunistic Infections. 2014;Oral presentation. Boston, MA.
101. Adams JL, Sykes C, Menezes P, et al. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?. J Acquir Immune Defic Syndr. 2013; 62 (3): 260-266.
102. Liu AY, Yang Q, Huang Y, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS ONE. 2014; 9 (1): e83736.
103. Kibengo FM, Ruzagira E, Katende D, et al. Safety, adherence and acceptability of intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant relationships: a randomized, clinical trial. PLoS ONE. 2013; 8 (9): e74314.
104. Bangsberg DR,. PReP adherence measurements. Microbicide Trials Network (MTN) Web site. http://www.mtnstopshiv.org/sites/default/files/attachments/ BangsbergREVISEDMicrobicideAdherenceMonitoring3-2011.pdf. Updated 2011. Accessed March 5, 2014.
105. Microbicide Trials Network (MTN). Backgrounder ASPIRE: A study to prevent infection with a ring for extended use. http://www.mtnstopshiv.org/news/ studies/mtn020/backgrounder. Updated 2013.Accessed March 11, 2014.
106. Microbicide Trials Network (MTN). Backgrounder MTN-017: Phase II safety and acceptability study of tenofovir gel reformulated for rectal use. http://www.mtnstopshiv.org/news/studies/mtn017/backgrounder. Updated 2013.Accessed March 11, 2014.
107. Hillier SL,. Safety and acceptability of coitally dependent use of 1% tenofovir over six months of use. Microbicides 2008 Conference. 2008;New Delhi, India:Abstract No. 655.
108. Consortium. FACTS. The follow-on African consortium for tenofovir studies (FACTS001) study. http://www.facts-consortium.co.za/?page-id=83.Updated 2013. Accessed December 10, 2013.
109. MTN020 Study Protocol. A multi-center, randomized, double-blind, placebo-controlled phase 3 safety and effectiveness trial of a vaginal matrix ring containing dapivirine for the prevention of HIV-1 infection in women. http://www.mtnstopshiv.org/sites/default/files/attachments/MTN- 020%20Version1%200-28September2011-CLEAN.pdf.Updated 2011. Accessed December 11, 2013.